Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

OMVOH - Health Canada Drug Approval Details

Approvals/Health Canada/OMVOH

Authorized

STANDARD

OMVOH

ELI LILLY CANADA INC🇨🇦 Health Canada

Approval Date: Feb 5, 2026
Approval ID: 7088e130ebf0b03a
Company: ELI LILLY CANADA INC
Type: Standard

Approval Details

Approval Id: 7088e130ebf0b03a
Drug Approval Canada Name: OMVOH
Product Name: OMVOH
Status: Marketed
Status Date: 2025-10-22
Original Market Date: 2025-10-22
Drug Class: Human
Dosage Form: Kit
Route Of Administration: Subcutaneous
Schedule: Schedule D , Prescription
Ahfs: 56:44.00
Atc Original: L04AC24 MIRIKIZUMAB
Aig Number: 0267731001
Company Name: ELI LILLY CANADA INC
Company Address: SUITE 900 Exchange Tower, 130 King Street West Toronto Ontario Canada M5X 1B1

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Feb 5, 2026

Approval ID

7088e130ebf0b03a

Type

Standard

Back to Health Canada Approvals